# NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

> **NCT06459869** · PHASE1 · RECRUITING · sponsor: **Akamis Bio** · enrollment: 30 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer (LARC)

## Interventions

- **DRUG:** NG-350A IV administration
- **DRUG:** Capecitabine oral administration
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT06459869
- **Lead sponsor:** Akamis Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-07
- **Primary completion:** 2026-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06459869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06459869, "NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06459869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*